| __timestamp | Mesoblast Limited | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 25434000 | 16606000 |
| Thursday, January 1, 2015 | 23783000 | 21497000 |
| Friday, January 1, 2016 | 29763000 | 25462000 |
| Sunday, January 1, 2017 | 12065000 | 28195000 |
| Monday, January 1, 2018 | 5508000 | 33078000 |
| Tuesday, January 1, 2019 | 75173000 | 36523000 |
| Wednesday, January 1, 2020 | 81497000 | 41455000 |
| Friday, January 1, 2021 | 85731000 | 74400000 |
| Saturday, January 1, 2022 | 63572000 | 101582000 |
| Sunday, January 1, 2023 | 54922000 | 112903000 |
| Monday, January 1, 2024 | 41070000 |
Unleashing the power of data
In the ever-evolving landscape of biotechnology, understanding cost structures is crucial. From 2014 to 2023, Veracyte, Inc. and Mesoblast Limited have shown distinct trajectories in their cost of revenue. Veracyte, Inc. has seen a remarkable increase, with costs rising by approximately 580% from 2014 to 2023, peaking in 2023. This reflects their aggressive expansion and scaling efforts. In contrast, Mesoblast Limited's cost of revenue peaked in 2021, with a 237% increase from 2014, before declining by 52% in 2023. This suggests a strategic shift or operational efficiency improvements. Notably, data for Veracyte, Inc. in 2024 is missing, indicating potential reporting delays or strategic changes. These insights provide a window into the financial strategies of these biotech firms, highlighting the dynamic nature of the industry.
Analyzing Cost of Revenue: Eli Lilly and Company and Veracyte, Inc.
Cost of Revenue: Key Insights for AstraZeneca PLC and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Veracyte, Inc.
Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down GSK plc and Mesoblast Limited's Expenses
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Veracyte, Inc.
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Mesoblast Limited
Cost of Revenue: Key Insights for Walgreens Boots Alliance, Inc. and Veracyte, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Mesoblast Limited
Comparing Cost of Revenue Efficiency: Veracyte, Inc. vs Amphastar Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Mesoblast Limited and Taro Pharmaceutical Industries Ltd.